Maravai LifeSciences Sees Unusually Large Options Volume (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) was the target of unusually large options trading on Wednesday. Stock traders bought 1,002 put options on the company. This represents an increase of 1,791% compared to the typical volume of 53 put options.

Insider Transactions at Maravai LifeSciences

In related news, insider Carl Hull bought 175,000 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was bought at an average price of $5.64 per share, with a total value of $987,000.00. Following the completion of the transaction, the insider now directly owns 175,000 shares of the company’s stock, valued at approximately $987,000. This represents a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.63% of the company’s stock.

Institutional Investors Weigh In On Maravai LifeSciences

Large investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp raised its holdings in shares of Maravai LifeSciences by 30.1% during the second quarter. Bank of New York Mellon Corp now owns 506,413 shares of the company’s stock valued at $3,626,000 after buying an additional 117,120 shares during the last quarter. Dragoneer Investment Group LLC bought a new stake in Maravai LifeSciences during the 2nd quarter valued at $5,373,000. Principal Financial Group Inc. boosted its position in Maravai LifeSciences by 62.4% during the 2nd quarter. Principal Financial Group Inc. now owns 666,187 shares of the company’s stock worth $4,770,000 after acquiring an additional 255,990 shares during the period. Royce & Associates LP boosted its position in Maravai LifeSciences by 130.4% during the 3rd quarter. Royce & Associates LP now owns 908,778 shares of the company’s stock worth $7,552,000 after acquiring an additional 514,332 shares during the period. Finally, Sivik Global Healthcare LLC grew its stake in shares of Maravai LifeSciences by 23.3% in the second quarter. Sivik Global Healthcare LLC now owns 450,000 shares of the company’s stock worth $3,222,000 after purchasing an additional 85,000 shares in the last quarter. 50.25% of the stock is owned by institutional investors and hedge funds.

Maravai LifeSciences Stock Performance

Maravai LifeSciences stock opened at $5.33 on Thursday. The company has a debt-to-equity ratio of 0.89, a current ratio of 10.74 and a quick ratio of 9.94. Maravai LifeSciences has a 12 month low of $4.28 and a 12 month high of $11.56. The company has a fifty day moving average price of $6.12 and a two-hundred day moving average price of $7.55. The company has a market cap of $1.35 billion, a PE ratio of -3.25 and a beta of -0.07.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on MRVI shares. The Goldman Sachs Group lowered Maravai LifeSciences from a “neutral” rating to a “sell” rating and dropped their target price for the stock from $7.00 to $4.25 in a research report on Thursday, December 5th. Royal Bank of Canada cut their target price on Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th. Robert W. Baird reduced their target price on Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating for the company in a research note on Friday, November 8th. William Blair restated a “market perform” rating on shares of Maravai LifeSciences in a research note on Friday, November 8th. Finally, Wolfe Research initiated coverage on shares of Maravai LifeSciences in a research note on Thursday, November 14th. They set a “peer perform” rating on the stock. One investment analyst has rated the stock with a sell rating, five have given a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Maravai LifeSciences currently has a consensus rating of “Hold” and a consensus target price of $10.28.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.